Legend Biotech (NASDAQ:LEGN - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.22, Briefing.com reports. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.22%. The business had revenue of $160.20 million for the quarter, compared to the consensus estimate of $143.91 million. During the same period last year, the firm posted ($0.17) earnings per share. The company's revenue was up 66.9% compared to the same quarter last year.
Legend Biotech Price Performance
Legend Biotech stock traded down $0.83 during trading hours on Wednesday, hitting $39.35. The stock had a trading volume of 1,169,212 shares, compared to its average volume of 1,092,352. The company has a quick ratio of 4.78, a current ratio of 4.84 and a debt-to-equity ratio of 0.25. Legend Biotech has a 1-year low of $38.60 and a 1-year high of $70.13. The stock's fifty day moving average is $46.86 and its two-hundred day moving average is $48.40.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $73.00 price objective on shares of Legend Biotech in a report on Wednesday. Scotiabank boosted their target price on Legend Biotech from $70.00 to $76.00 and gave the company a "sector outperform" rating in a research report on Monday, August 12th. Redburn Atlantic initiated coverage on Legend Biotech in a research note on Tuesday, October 8th. They set a "buy" rating and a $86.00 target price on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $86.00 price objective on shares of Legend Biotech in a report on Tuesday, October 29th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $81.46.
Read Our Latest Stock Analysis on LEGN
Legend Biotech Company Profile
(
Get Free Report)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Articles
Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
